stanozolol has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brasil, GA; da Silva, CL; de Andrade, TU; de Lima, EM; de Souza Andrade Moraes, F; do Nascimento, AM; Dubois Filho, DG; Falsoni, RMP; Haguihara, SCGC | 1 |
| Chen, Y; Wang, S; Zheng, Y; Zhu, X; Zou, Y | 1 |
2 other study(ies) available for stanozolol and Disease Exacerbation
| Article | Year |
|---|---|
Stanozolol promotes lipid deposition in the aorta through an imbalance in inflammatory cytokines and oxidative status in LDLr knockout mice fed a normal diet.
Topics: Anabolic Agents; Animals; Aorta; Atherosclerosis; Cytokines; Disease Models, Animal; Disease Progression; Inflammation; Inflammation Mediators; Lipid Metabolism; Lipoproteins, LDL; Male; Mice; Mice, Knockout; Oxidation-Reduction; Oxidative Stress; Receptors, LDL; Stanozolol | 2019 |
The progression risk factors of children with transfusion-independent non-severe aplastic anemia.
Topics: Adolescent; Anemia, Aplastic; Blood Transfusion; Child; Child, Preschool; Cyclosporine; Disease Progression; Female; Follow-Up Studies; Humans; Infant; Male; Palliative Care; Prognosis; Retrospective Studies; Risk Factors; Stanozolol | 2013 |